​[주제 세부 소개] 

[연사 소개]

저희 마루젠 제약은 1938년의 설립되었으며 자연계의 유용 식물을 중심으로 추출 방법을 구사해, 고객의 만족, 안전성이 높은 기능성 성분을 추구해왔습니다. 이번의 화자인 야마자키는 연세 대학교 어학당을 졸업 후, 해외 영업팀 기술 영업직으로 8년에 걸쳐 한국 국내에 저희 식품 원료 , 화장품 원료를 제안하고 있습니다.​​ 

[주제 세부 소개]

Lipid-based excipients have emerged as key enablers in the advancement of modern drug delivery systems, offering unique physicochemical properties that make them especially suitable for complex therapeutic applications. Among their many uses, their role in the oral delivery of biopharmaceuticals has seen remarkable growth in recent years. This is particularly significant given the challenges associated with delivering biopharmaceuticals, such as insulin, which are typically large, hydrophilic, and structurally unstable molecules. These properties make them highly susceptible to enzymatic degradation and poor absorption in the gastrointestinal tract, thereby necessitating the development of robust stabilization and delivery strategies.

This presentation focuses on insulin as a model biopharmaceutical and introduces recent advances in oral delivery strategies using lipid-based approaches. In particular, it will highlight the effectiveness of specific lipid excipients in enhancing the performance of Hydrophobic Ion Pairing (HIP) technology. By forming complexes that increase the lipophilicity and stability of insulin, HIP combined with lipids represents a promising strategy to overcome traditional barriers to oral protein delivery. Case studies from recent experimental research will be presented to demonstrate the practical benefits and future potential of lipid-assisted HIP systems in biopharmaceuticals formulation. 

[연사 소개]

Professor Lee received a bachelor's degree from College of Pharmacy, Chung-Ang University in 1997, followed by a master's and Ph.D. in Pharmacy from the same institution. After completing his academic training, he gained four years of industry experience at Daewoong pharmaceutical company, where he was involved in hands-on research and development. He then held academic positions at department of pharmaceutical engineering, Inje university and College of pharmacy, Keimyung University before joining Chung-Ang University, where he currently serves as a full professor. His primary research interests focus on the brain drug delivery, cancertherapy to overcome resistant ovarian cancer, and he has conducted extensive studies on oral peptide drug delivery systems using lipid-based materials.​ 

[주제 세부 소개]

Besides low aqueous solubility, poor absorption is a limitation to oral efficiency for a growing number of small and large molecules, including peptides, which are also prone to degradation in the GI tract. Multifunctional lipid excipients, particularly medium-chain fatty acid esters, are emerging as promising tools to overcome these barriers.

This presentation will briefly revisit the physiological role of tight junctions and explore how targeted modulation can enhance paracellular transport. Drawing on recent ex vivo and in vivo studies, we will showcase the efficacy and safety of these lipid-based excipients in improving the permeation of both small molecules and peptides.

Despite their permeation-enhancing properties being only recently elucidated, these excipients have a well-established track record in pharmaceutical development. They are present in several marketed formulations, compliant with major pharmacopeias, and manufactured by Gattefossé under responsible and sustainable practices. Their versatility allows for easy integration into both liquid and solid oral dosage forms—making them a practical and innovative solution for peptide delivery. 

[연사 소개]

PhD in Pharmaceutical Sciences, with 25 years of experience in pharmaceutical development, covering generic drugs, OTC products, veterinary medicine, pharmaceutical contract manufacturing, and prescription specialties. Career marked by responsibilities across the entire value chain, from preclinical stages to product launch, within companies such as Pierre Fabre, Ethypharm, Virbac, Sanofi, and STA Pharmaceuticals.

Since 2022, leading the Pharmaceutical Business Unit at Gattefossé, with responsibility for global innovation and commercial development of lipid-based excipients. ​